EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches

Danielle Rasooly iD, Alexandre C Pereira, Jacob Joseph

International Journal of Molecular Sciences · 17.03.2025 · 26 (6) · 2703

DOI: 10.3390/ijms26062703 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.03.2025. Verfasst von Danielle Rasooly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Massachusetts Veterans Epidemiology Research and Information Collaborative (MAVERIC), Veterans Affairs Healthcare System, 150 S. Huntington Ave., Bos…. Hauptthemen laut MEDLINE: Heart Failure, Drug Discovery, Genomics, Drug Development. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heart failure (HF) is a complex, heterogeneous syndrome with rising prevalence and high morbidity and mortality. The pathophysiology and diverse etiologies of HF present significant challenges for developing effective therapies. Omics technologies—including genomics, proteomics, transcriptomics, metabolomics, and epigenomics—have reshaped our understanding of HF at the molecular level, uncovering new biomarkers and potential therapeutic targets. Omics also enable insights into individualized treatment responses, the risks of adverse drug effects, and patient stratification for clinical trials. This review explores how multi-omics can enhance heart failure drug discovery and development across all stages of the therapeutic pipeline: (1) target selection and lead identification, (2) preclinical studies, and (3) clinical trials. By integrating omics approaches throughout the drug development process, we can accelerate the discovery of more effective and personalized therapies for heart failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureDrug DiscoveryGenomicsDrug DevelopmentHumansMetabolomicsProteomicsAnimalsBiomarkersEpigenomicsMultiomics

Stichwörter der Autor:innen

clinical trialsdrug discoveryepigenomicsgenomicsheart failuremetabolomicsmulti-omicsomicsproteomicstranscriptomics

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Massachusetts Veterans Epidemiology Research and Information Collaborative (MAVERIC), Veterans Affairs Healthcare System, 150 S. Huntington Ave., Boston, MA 02130, USA.
  • Division of Aging, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA 02130, USA.
  • Cardiology Section, VA Providence Healthcare System, 830 Chalkstone Avenue, Providence, RI 02908, USA.
  • Department of Medicine, The Warren Alpert Medical School, Brown University, 222 Richmond St., Providence, RI 02903, USA.

ORCID-Profile: Danielle Rasooly

Zitieren

APA

Rasooly, D., Pereira, A. C., & Joseph, J. (2025). Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches. International Journal of Molecular Sciences, 26(6), 2703. https://doi.org/10.3390/ijms26062703

Vancouver

Rasooly D, Pereira AC, Joseph J. Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches. International Journal of Molecular Sciences. 2025;26(6):2703. doi:10.3390/ijms26062703

BibTeX
@article{Rasooly2025,
  author = {Rasooly, Danielle and Pereira, Alexandre C and Joseph, Jacob},
  title = {Drug Discovery and Development for Heart Failure Using Multi-Omics Approaches},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  volume = {26},
  number = {6},
  pages = {2703},
  doi = {10.3390/ijms26062703}
}
Kostenlos starten →